Mitsubishi Tanabe Pharma Corporation revised consolidated financial forecasts for six months ending September 30, 2017 and fiscal year ending March 31, 2018. For the six months ending September 30, 2017, the company revised in forecast to revenue of ¥213,000 million, core operating profit of ¥39,500 million, operating profit of ¥36,500 million, profit before tax of ¥37,000 million net profit for the period of ¥28,000 million and net profit attributable to owners of the company of ¥29,500 million against its previous forecast of revenue of ¥212,500 million, core operating profit of ¥41,500 million, operating profit of ¥40,500 million, profit before tax of ¥41,000 million net profit for the period of ¥31,000 million and net profit attributable to owners of the company of ¥32,500 million. Net profit per share was expected to be ¥52.59 per share against its previous forecast of ¥57.93 per share For the fiscal year ending March 31, 2018, the company revised in forecast to revenue of ¥433,000 million, core operating profit of ¥80,000 million, operating profit of ¥81,000 million, profit before tax of ¥82,000 million net profit for the period of ¥60,000 million and net profit attributable to owners of the company of ¥63,500 million against its previous forecast of revenue of ¥441,000 million, core operating profit of ¥90,000 million, operating profit of ¥90,000 million, profit before tax of ¥91,000 million net profit for the period of ¥68,000 million and net profit attributable to owners of the company of ¥71,500 million. Net profit per share was expected to be ¥113.22 per share against its previous forecast of ¥127.45 per share.